CANbridge Pharmaceuticals CEO, James Xue, Named as Termeer Foundation Mentor
To Provide Mentoring to Emerging Life Science Leaders in Rare Disease
Support Termeer Foundation’s Mission of Connecting Leaders to Catalyze New Treatments
BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)--CANbridge Pharmaceuticals, Inc., a biopharmaceutical company developing and commercializing innovative drugs to treat rare diseases and rare cancers in China and globally, announced that James Xue, Ph.D., Founder, Chairman and CEO of CANbridge Pharmaceuticals, has been invited to serve as a Termeer Foundation Mentor by the Termeer Foundation. Dr. Xue joins 22 other global life science industry leaders, distinguished by both their professional accomplishments and their desire to develop others in the field. Termeer Foundation Mentors provide mentorship to the Henri Termeer Fellows, typically company founders and first-time CEOs, who are invited to join the Henri Termeer Network, a group of emerging and established healthcare leaders who pool their collective experience to advance cures. The Termeer Foundation has awarded 20 fellowships since 2018.
“I spent some of my most formative career years at Genzyme working under the brilliant and inspiring direction of Henri Termeer, who was also a mentor and the Founding Chair of the CANbridge Advisory Board,” said James Xue, Ph.D., Founder, Chairman and CEO of CANbridge Pharmaceuticals. “I believe deeply in the Termeer Foundation vision of a life science world made better by connecting and pooling the experience of its leaders to create treatments that can change lives, as Henri did. As a leader in the rare disease space in China and globally, I believe that CANbridge has a unique perspective which I look forward to sharing with the industry’s emerging innovators.”
“We are delighted to welcome James to the Termeer Network as a Mentor, where we know his talents, experience and dedication to the rare disease world will aptly carry out the vision of the Termeer Foundation and be a fitting tribute to the mentorship Henri provided to him,” said Belinda Termeer, President, Co-Founder and Member of the Board of Directors of The Termeer Foundation.
Dr. Xue is also the Co-Founder and Deputy Director General of China Alliance for Rare Disease (CARD); Deputy Director General of Shanghai Foundation for Rare Disease; Vice Chair of the R&D Committee of China Pharmaceutical Innovation and Research Development Association (PHIRDA), and a member of the Advisory Committee of the Joint Institute of Peking University Health Science Center and University of Michigan Medical School.
About The Termeer Foundation
Building on the bold legacy of Henri Termeer, who pioneered groundbreaking treatments for rare diseases, The Termeer Foundation connects life science innovators and catalyzes the creation of new medicines. The Foundation’s network of emerging and established healthcare innovators cultivates tomorrow’s leaders and leverages their collective expertise to solve complex problems in drug development and accessibility. The Foundation also integrates its network with academic institutions, nonprofits, regulatory agencies and other organizations across the global healthcare ecosystem to provide expert counsel, stimulate innovation, eliminate barriers to progress, and ultimately connect the world of healthcare until every patient has a cure. Visit us at www.termeerfoundation.org or on LinkedIn @TermeerFoundation.
About CANbridge Pharmaceuticals Inc.
CANbridge Pharmaceuticals Inc. is a biopharmaceutical company accelerating development and commercialization of treatments for orphan diseases and rare cancers to address unmet medical needs. CANbridge has a global partnership with WuXi Biologics to develop and commercialize proprietary therapeutics for the treatment of rare genetic diseases. In greater China, where it is a recognized leader in rare diseases, CANbridge has an exclusive licensing agreement to commercialize Hunterase®, an enzyme replacement therapy for the treatment of Hunter syndrome (also known as mucopolysaccharidosis type II), developed by GC Pharma and marketed in more than 12 countries worldwide. CANbridge also has entered into a strategic collaboration and licensing agreement with LogicBio Therapeutics to develop, manufacture and commercialize gene therapy candidates for treatments for Fabry and Pompe diseases. CANbridge also has a collaborative agreement with the Horae Gene Therapy Center at UMass Medical School for the research and development of gene therapies to treat rare genetic diseases.
For more on CANbridge Pharmaceuticals Inc., please go to: www.canbridgepharma.com.